clonazepam (Klonopin)

How long the trials actually ran

The longest trial behind the clonazepam approval ran 9 weeks.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

How many Americans take clonazepam

Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.

11,861,002

prescriptions in the United States (2024)

2,154,593

people filling them (2024)

Prescriptions are down 44% since 2014. Whatever you decide about clonazepam, you are deciding alongside about 2,154,593 other people this year.

Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.

What people report to the FDA about clonazepam

159,283

reports mentioning clonazepam, all time

108,457

filed as serious (a report-level flag covering every drug and outcome in the report)

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.

Known interactions, from the label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

FDA label for clonazepam, effective August 27, 2026 — DailyMed.

Who pays for clonazepam

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D

Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 1,315,917 beneficiaries filled 8,856,358 claims in 2024 — 925,485 aged 65 and over, and 390,432 under 65.

Medicaid

At least 3,836,777 prescriptions in 2024 — a floor, because 151 of 670 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.

All payers (survey estimate)

The MEPS-based estimate above puts the whole country at 11,861,002 prescriptions and 2,154,593 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.

The population nobody counts

The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of clonazepam specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

The approval, step by step

1. Step 1

   What the approval was actually based on

   Which studies did the FDA rely on, how long did they run, and who was in them?

   Study 1 was a 9-week, fixed-dose study involving clonazepam doses of 0.5, 1, 2, 3 or 4 mg/day or placebo... A significant difference from placebo was observed consistently only for the 1 mg/day group. The difference between the 1 mg dose group and placebo in reduction from baseline in the number of full panic attacks was approximately 1 panic attack per week.

   FDA-approved labelling, Clinical Trials: (from a generic manufacturer's label — the brand application has no current label on file, so this text is FDA-cleared but is not the original approval document) — read the label on DailyMed

   Our reading

   Read the effect size, because it is stated plainly and almost never repeated: about one fewer panic attack per week. And of five doses tested, only 1 mg/day separated from placebo consistently — the higher doses did not do better. The study ran nine weeks, of which six were at a fixed dose. Clonazepam is prescribed for years. Note also where this quote comes from: the brand label is gone and this text is a generic filer's, headed "Clinical Trials:" with no section number, because the drug predates the rule that created section 14.

2. Step 2

   The approval

   When was it approved, under what application, and by whose review?

   Approved

   June 4, 1975

   Application

   NDA017533

   Review

   PRIORITY

   Original sponsor

   Roche

   Holds it now

   Cheplapharm

   Label submissions since

   51

   Source: openFDA Drugs@FDA, original application ORIG-1

3. Step 3

   What was added after it was on the market

   Which warnings arrived only after millions of people were already taking it?

   • The FDA strengthened the benzodiazepine warning in 2020

     45 years after approval

     In September 2020 the FDA required the boxed warning on every benzodiazepine to be rewritten. The wording matters: physical dependence can develop even when the medication is taken exactly as prescribed, and stopping abruptly or dropping the dose quickly can cause withdrawal reactions that include seizures and can be life-threatening.

     This is not a claim that the medication is bad or that you should stop taking it. It is the opposite. It is the reason not to stop on your own. The FDA's own instruction to prescribers is to taper gradually rather than stop, and to reassess dose and duration over time.

     Worth asking

     How long is the plan for me to be on this, what does my taper look like if we decide to come off, and how will we tell withdrawal apart from my original anxiety coming back.

     FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class — U.S. Food and Drug Administration (2020)

4. Step 4

   What independent research has found since

   What has been learned by people who were not selling it?

   • Withdrawal from these medications can take months, and NICE says so

     47 years after approval

     NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.

     It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.

     That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.

     Worth asking

     Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.

     Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215) — National Institute for Health and Care Excellence (2022)

   • Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study

     41 years after approval

     Following 3,434 adults aged 65+ for a mean of 7.3 years (797 developed dementia), the heaviest benzodiazepine users had no higher dementia risk than non-users — only minimal users showed a slight elevation — which argues against benzodiazepines causing dementia.

     Worth asking

     The evidence on benzodiazepines and dementia points both ways — how do you weigh it for someone my age, and does it change how long I should stay on clonazepam?

     Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study — Gray SL, et al. (2016)

   • Benzodiazepine use and risk of Alzheimer's disease: case-control study

     39 years after approval

     Comparing 1,796 older adults with Alzheimer's disease to 7,184 matched controls, past benzodiazepine use was associated with higher Alzheimer's risk, and the association strengthened with longer cumulative use — an association that cannot by itself prove the drugs cause dementia.

     Worth asking

     I've been on clonazepam for more than a few months — given the unresolved question about benzodiazepines and dementia, is it worth working out a gradual tapering plan?

     Benzodiazepine use and risk of Alzheimer's disease: case-control study — Billioti de Gage S, et al. (2014)

   • Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety,…

     22 years after approval

     In 413 people with panic disorder randomized to placebo or five fixed doses of clonazepam, daily doses of 1 mg and above reduced panic attacks equally well, and 1-2 mg/day gave the best balance of benefit against side effects such as sleepiness and unsteadiness, which climbed at 3-4 mg.

     Worth asking

     I'd like to check my clonazepam dose — am I in the 1-2 mg range where benefit plateaus, and if I'm above it, is the extra dose doing anything but adding side effects?

     Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance — Rosenbaum JF, et al. (1997)

   • Treatment of social phobia with clonazepam and placebo.

     18 years after approval

     In a 10-week double-blind trial of 75 outpatients with social phobia, 78% responded to clonazepam (mean maximum dose 2.4 mg/day) versus 20% on placebo, with more unsteadiness and dizziness in the clonazepam group.

     Worth asking

     If clonazepam is helping my social anxiety, what's the longer-term plan — is this a bridge to something like an SSRI or therapy, or are we staying on it?

     Treatment of social phobia with clonazepam and placebo. — Davidson JR, et al. (1993)

   • Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

     36 years after approval

     In 120 adults with panic disorder randomized to clonazepam or paroxetine for 8 weeks, both drugs reduced panic attacks (0.1 vs 0.5 attacks per week at endpoint), and fewer clonazepam patients reported side effects (73% vs 95%).

     Worth asking

     Between a benzodiazepine like clonazepam and an SSRI like paroxetine, which is the better long-term strategy for my panic attacks given dependence risk?

     Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine — Nardi AE, et al. (2011)

5. Step 5

   What still is not known

   Which questions you might reasonably have has nobody answered yet?

   • One fewer panic attack per week, at one specific dose, over nine weeks. Is that the size of benefit you were told to expect?
   • The higher doses were not better than 1 mg/day. If you are above that, what is the reason?
   • Physical dependence on benzodiazepines develops within weeks. The trial barely outlasted the window in which it begins, and the boxed warning about it was not strengthened until 2020.